Adverse events · healthy, full‐term (37 to 42 weeks), formula‐fed infants
High‐protein formula showed no clear difference in adverse events compared with standard‐protein formula (low certainty).
1 finding from 1 review
Adverse events · healthy, full‐term (37 to 42 weeks), formula‐fed infants
Standard‐protein formula showed no clear difference in adverse events compared with low‐protein formula (low certainty).
1 finding from 1 review
Adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with chronic pouchitis or ileal pouch‐anal anastomosis
De Simone Formulation showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · Patients with ileal pouch‐anal anastomosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
Elemental formula supplements showed no clear difference in withdrawals due to adverse events compared with polymeric formula supplements (low certainty).
1 finding from 1 review
Severe adverse events · patients with initial treatment of HIV infection in antiretroviral‐naive individuals
Co‐formulated abacavir‐lamivudine‐zidovudine showed no clear difference in severe adverse events compared with NNRTIs or PIs (moderate certainty).
1 finding from 1 review
Adverse events · Participants with Crohn's disease in remission
1 finding from 1 review
Serious adverse events · Participants with Crohn's disease in remission
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
1 finding from 1 review
Proportion of participants with ≥ 1 serious adverse events · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events Maximum · chronic hepatitis B
It is very uncertain whether xiao Chai Hu Tang formula changes proportion of participants with ≥ 1 adverse events considered 'not… compared with no intervention (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
It is very uncertain whether four‐food elimination and amino acid formula changes withdrawals due to adverse events at 6 weeks compared with four‐food elimination diet (very low certainty).
1 finding from 1 review
Patients with one or more adverse events · Patients requiring surgical removal of a lower wisdom tooth or teeth, with baseline moderate to severe pain (surgery under local…
Paracetamol (single oral dose, any dose or formulation; subgroups up… showed no clear difference in patients with one or more adverse events compared with placebo; GRADE not reported.
1 finding from 1 review
Adverse events · patients with acute pancreatitis
It is very uncertain whether enteral nutrition changes adverse events compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events · patients with acute pancreatitis
It is very uncertain whether immunonutrition changes adverse events compared with control (very low certainty).
1 finding from 1 review
Adverse events · patients with acute pancreatitis
Probiotics showed no clear difference in adverse events compared with control (low certainty).
1 finding from 1 review
Serious adverse events · Patients with quiescent ulcerative colitis
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).
1 finding from 1 review